tbuckley/cabot-search huggingface dataset:
PTU-167 Enhanced recovery for laparoscopic colorectal resection: is there a role for transcutaneous electrical nerve stimulation?
Authors: C El-Sayed, D Singh-Ranger, I Aslam, M Khan, J Francombe
Journal: Gut (2015)

<h3>Introduction</h3> Transcutaneous electrical nerve stimulation (TENS) is a recognised modality for pain control. Evidence for its use in enhanced recovery programmes is limited. This pilot study aimed to investigate the role of TENS in pain control, ileus and duration of stay in patients undergoing elective colorectal surgery within an enhanced recovery programme. <h3>Method</h3> Patients undergoing elective laparoscopic colorectal resection were given TENS twice daily for thirty minutes. This was in addition to standard analgesic and fluid regimens. Patients completed a visual analogue score (VAS) pain questionnaire daily during the post-operative period. Pain was assessed at three points: 1. At rest, 2. Transferring out of bed, 3. Mobilisation. The difference in pain scores, analgesic requirements, time to first flatus and hospital stay were recorded. <h3>Results</h3> Seven patients used the TENS machine, four patients were controls. The median age was 77 years (61–79). The higher the VAS score, the greater the pain. The average pain score over four days in the TENS group vs. control group at rest, transfer and mobilisation was 30.9 vs. 47; 49.6 vs. 57.8 and 39.7 vs. 55.3 respectively. The differences between TENS and the control group were significant at rest (p = 0.046) and mobilisation (p = 0.040). The average cumulative paracetamol and ibuprofen dose in TENS patients was reduced compared to the control group (1.5 g vs. 2.6 g) and (2 g vs. 2.75 g) respectively. TENS reduced hospital stay (5.6 vs. 6.6 days) and reduced the time to pass flatus (1.75 vs. 2 day). This trend was not significant. <h3>Conclusion</h3> TENS is recommended as an effective addition to an enhanced recovery programme in patients undergoing laparoscopic colorectal surgery. TENS significantly reduced post operative pain at rest and transfer. There was also a trend in reduction of ileus, analgesic use and length of stay. <h3>Disclosure of interest</h3> None Declared.
Concanavalin A and the Production of Bovine Leukemia Virus Antigen in Short-Term Lymphocyte Cultures2
Authors: D. M. Driscoll, L. E. Baumgartener, C. Olson
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Concanavalin A and the Production of Bovine Leukemia Virus Antigen in Short-Term Lymphocyte Cultures Get access D. M. Driscoll, D. M. Driscoll Search for other works by this author on: Oxford Academic PubMed Google Scholar L. E. Baumgartener, L. E. Baumgartener Search for other works by this author on: Oxford Academic PubMed Google Scholar C. Olson C. Olson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 5, May 1977, Pages 1513–1514, https://doi.org/10.1093/jnci/58.5.1513 Published: 01 May 1977 Article history Received: 14 July 1976 Accepted: 24 November 1976 Published: 01 May 1977
Parabiotic Cell Culture. IV. Interaction Between Normal and Ascites Tumor Cells of Rats&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Hajim Katsuta, Toshiko Takaoka
Journal: JNCI Journal of the National Cancer Institute (1964)

With the use of the parabiotic cell culture method, interaction between the cells from normal tissue (liver cells, heart fibroblasts, and kidney epithelial cells) and transplantable ascites tumor cells (Hepatoma AH-130 and Yoshida sarcoma cells) of rats was examined quantitatively by cell counting. The experiments were planned to reproduce conditions in vivo of tumor growth, e.g., a situation in which tumor cells are rapidly proliferating and a primary culture of normal cells is maintained at a constant population level. In the combination of liver and hepatoma cells, or fibroblasts and sarcoma cells, the proliferation of tumor cells was apparently accelerated in the parabiotic culture, while normal cells were inhibited or destroyed. The fact that this interaction was further accelerated when these cells were cultivated together in a single tube suggests the possibility of direct action by cell contact. In other combinations between these normal and tumor cells, little interaction was observed.
Nicotine Patches Effective in the Absence of Behavioral Support
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of advanced non-small cell lung cancer (NSCLC) with a biweekly schedule of irinotecan (I), paclitaxel, and cisplatinum (P): A phase II study
Authors: M. Gonzalez, J. Rebollo, R. Rami, J. Belda, J. Farré, I. Azinovic, A. Crespo, A. Brugarolas
Journal: Journal of Clinical Oncology (2009)

e19076 Background: Irinotecan, paclitaxel (taxol, T), and cisplatinum are among the most active agents in the treatment of NSCLC, given alone as single agents or in combination. Based in previous data (Proc ASCO 2003 # 2816), we performed a confirmatory phase II study of the activity of a bi-weekly combination of I (120 mg/m2), T(60 mg/m2) and P (40 mg/m2) in advanced NSCLC. Methods: Forty-three patients (pts) (37 male, 6 female) with histologically proven IIIA-IV NSCLC were treated at our institution. Median age was 61 years (33–79). All pts were ECOG 0–2. 14 pts had locally advanced disease (8 IIIA, 6 IIIB) and 29 metastatic disease. Previous treatments included surgery (5 pts), radiotherapy (4 pts), chemotherapy (5 pts), surgery + radiotherapy (3 pts) and surgery + chemotherapy (2 pt). In three cases, treatment was administered as adjuvant after resection of a primary (2 cases) or a metastatic tumor (1 case). Results: A total of 299 courses were administered (median 6, range 2–14). Toxic episodes grade III-IV were neutropenic fever (10/299; 3.3%), anemia (1/299; 0.3%), asthenia (3/299; 1%), diarrhea (5/299; 17%), hemorrhagic colitis (1/299; 0.3%), mucositis (2/299, 0.6%), vomiting (4/299; 1.3%) and peripheral neuropathy (1/299; 0.3%). With a median follow-up of 72 months (9–97), 2 pts (4.6%) presented pathological complete response, 26 (60%) partial response, 11 (25%) stable disease and 1 pt progressed. Four partial responders were rendered free of disease after rescue surgery. Median time to progression was 6 months. Median survival was 10 months. The actuarial 2 and 5-year overall survival are 26% and 13% respectively. Conclusions: I, T and P at the referred doses can be safely administered in a bi-weekly basis, with a good tolerance and response rate in advanced NSCLC pts. No significant financial relationships to disclose.
PWE-065 Stopping biological therapy in patients with inflammatory bowel disease: a 5 year review of a single centre–s experience
Authors: V Dattani, K Lithgo, T Price, MW Johnson
Journal: Gut (2015)

<h3>Introduction</h3> With the recent NICE guidelines giving clearance for the use of infliximab, golimumab and adalimumab in moderate-severe ulcerative colitis, there is a general fear held by the Clinical Commissioning Groups (CCGs) that the cost of biological therapy is about to rapidly escalate. Cheaper biosimilars will soon join the market place, but already many CCGs have restricted funding to just 1 year and advocate stopping if the patient is in clinical remission. Given these funding restrictions we assess the outcomes seen in those patients stopping biological therapy. <h3>Method</h3> A 5 year retrospective review was made of the 94 inflammatory bowel disease (IBD) patients that have been treated with biologics at the Luton and Dunstable University Hospital. Data was obtained from the National IBD Registry, Evolve (the hospital’s electronic note system), and ICE (the hospitals results system). Full remission was defined as asymptomatic patients with near normal inflammatory markers and complete mucosal healing or minimal endoscopic inflammation only. <h3>Results</h3> There were 94 IBD patients treated with biological therapy between January 2010 and December 2014. Biologics were stopped in 49 patients, of which 36 were deemed to be in full remission. Biological therapy was also stopped because of treatment failure requiring surgery (eg.colectomy) in 6, 2 were in remission but needed surgery for subsequent colorectal cancer, 3 patients fell pregnant (all initially in clinical remission, although 2 subsequently flared and were restarted), the injection was too painful for 2, 1 was non-compliance and 1 had an infusion reaction. In the group of 36 that achieved full remission (25CrD, 2CrD Fistulae, 9UC), 31 (86%) of them stayed in remission after stopping their biologics, with an average follow up time of 13 months (4–42 months), at the point of writing this abstract. Of the 5 patients in remission that flared, 2 CrD patients flared post-delivery, 1 UC patient flared, and 2 CrD patients flared with the complications of fistulae and/or strictures requiring surgery. Of the 13 patients who weren’t in remission on stopping the biologics, only 2 of them settled into remission using alternative therapies. <h3>Conclusion</h3> Provided patients are in a full remission our data supports an efficacy of 86% in stopping biological therapy and then managing patients on traditional immunosuppressor therapies, at least in the first year. Caution must however be observed, as 2 of the unpredictable relapses that did occur on stopping biological therapy resulted in young patients having to undergo surgery. A greater overall success rate may have been achieved with tighter initial case selection by gastroenterologists with a specialist experience in IBD or through open discussions at a Biologics MDT. <h3>Disclosure of interest</h3> None Declared.
Early findings in outbreak of haemolytic uraemic syndrome among young children caused by Shiga toxin-producing Escherichia coli, Romania, January to February 2016
Authors: Emilie Peron, Alina Zaharia, Lavinia Cipriana Zota, Ettore Severi, Otilia Mårdh, Codruta Usein, Mihaela Bălgrădean, Laura Espinosa, Josep Jansa, Gaia Scavia, Alexandru Rafila, Amalia Serban, Adriana Pistol
Journal: Eurosurveillance (2016)

As at 29 February 2016, 15 cases of haemolytic uraemic syndrome with onset between 25 January and 22 February were reported among children between five and 38 months in Romania, and three of them died. Cases were mostly from southern Romania. Six cases tested positive for Escherichia coli O26 by serology. Fruits, vegetables, meat and dairy products were among the possible common food exposures. Investigations are ongoing in Romania to control the outbreak.
State and trait in psychiatric practice
Authors: I Extein, M B Bowers
Journal: American Journal of Psychiatry (1979)

The authors present a schema for conceptualizing psychiatric illness in terms of state and trait disorders. These disorders are relatively independent components, one or both of which can be present in one patient. They usually require treatment by different methods. State disorders, such as schizophrenic psychosis, mania, and depression, are time-limited and autonomous and respond better to pharmacological than psychosocial therapy. Trait disorders, such as neurotic and characterological disturbances, are long-lasting and respond better to psychosocial therapies. The authors discuss the implications of this schema for the integration of pharmacological and psychosocial treatments.
Deficiency in Placental Growth Factor improves inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic mice
Authors: Christophe Van Steenkiste, Anja Geerts, Jordi Ribera, Sonia Tugues, Manuel Morales-Ruiz, Jean Marie Stassen, Peter Carmeliet, Ekhart Verdegem, Louis Libbrecht, Martine De Vos, Hans Van Vlierberghe, Isabelle Colle
Journal: Hepatology (2009)
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Authors: Muthiah Vaduganathan, Deepak L. Bhatt, Byron L. Cryer, Yuyin Liu, Wen-Hua Hsieh, Gheorghe Doros, Marc Cohen, Angel Lanas, Thomas J. Schnitzer, Thomas L. Shook, Pablo Lapuerta, Mark A. Goldsmith, Loren Laine, Christopher P. Cannon
Journal: Journal of the American College of Cardiology (2016)
Tumour Shrinkage and Response Outcomes During Second-Line Panitumumab (Pmab) + Folfiri Vs Folfiri Treatment
Authors: M. Peeters, T.J. Price, A. Cervantes, A. Sobrero, M.P. Ducreux, T. André, F. Lordick, C.J.A. Punt, R. Koukakis, J. Terwey, E. van Custem
Journal: Annals of Oncology (2014)
Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study
Authors: S. J. Lee, P. G. Richardson, P. Sonneveld, M. Schuster, D. Irwin, J. Massaro, B. Crawford, R. Dhawan, S. Gupta, K. C. Anderson
Journal: Journal of Clinical Oncology (2005)

6535 Background: A large randomized phase 3 study (APEX) (Blood 2004;104: Abstract 336.5) in relapsed MM demonstrated significant clinical benefits (time to progression, response, and survival) associated with bortezomib therapy over high-dose dexamethasone, with comparable grade 3 and 4 toxicities. HRQL data were prospectively collected during the study. Methods: Two HRQL instruments (EORTC QLQ-C30 and FACT/GOG-NTX) were administered at baseline, weeks 6, 12, 18, 24, 30, 36, and 42, or until discontinuation of protocol treatment. Data were analyzed based on modified intention-to-treat analysis; 44 of 642 patients were excluded due to no baseline or no follow-up HRQL data. At baseline, the 2 treatment groups were comparable on demographic and clinical characteristics, NTX score, and on most EORTC scores. There were substantial missing HRQL data (from 12.5% at week 6 to 75.6% at week 42), primarily due to premature closure of the study and disease progression. Extensive statistical analyses were undertaken to correct for potential bias related to the missing data. The a priori primary endpoint for the HRQL analyses was the Global Health Status scale of the EORTC. All other scales and symptom scores were considered secondary endpoints, and presented p values are adjusted for multiple comparisons by the Hochberg-Benjamini method. Results: Using generalized estimating equations (GEE) of multiply imputed datasets, a significant difference over the 42 weeks in favor of bortezomib was found for the primary endpoint of Global Health (p = 0.0005), as well as the secondary endpoints of Physical, Role, Cognitive, and Emotional Functioning (adjusted p values < 0.05), and the symptom scales of Nausea, Dyspnea, Sleep, Diarrhea, and Financial Impact (adjusted p values < 0.05). There was no HRQL domain for which high-dose dexamethasone was superior over time. Using alternative methods to adjust for potential informative censoring, both a Sun and Song analysis and a Pattern-Mixture model analysis supported the GEE conclusions. Conclusions: Bortezomib is associated with better HRQL compared with high-dose dexamethasone in the treatment of relapsed MM. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson Pharmaceutical Services, Millennium Mapi Values, Millennium Millennium Millennium, Speakers Bureau Mapi Values, Millennium
Evolution of the mouse beta-globin genes: a recent gene conversion in the Hbbs haplotype.
Authors: M A Erhart, K S Simons, S Weaver
Journal: Molecular Biology and Evolution (1985)

We have determined the complete nucleotide sequence of the two nonallelic adult beta-globin genes of the C57BL/10 mouse. These genes, designated beta s and beta t, show a sequence similarity of 99.6% over the region bordered by the translational start and stop codons. Both beta s and beta t encode functional polypeptide chains that are identical. A comparison of the C57BL/10 beta-globin haplotype, Hbbs, with that of the BALB/c mouse, Hbbd, suggests that the two haplotypes have distinct evolutionary histories. The two adult beta-globin genes of the Hbbd haplotype, beta dmaj and beta dmin, are 16% divergent at the nucleotide level and encode distinct polypeptides that are synthesized in differing amounts. Our analysis indicates that a gene correction mechanism has been operating on the Hbbs chromosome to keep beta s and beta t evolving in concert, whereas on the Hbbd chromosome, beta dmin has diverged considerably from beta dmaj. We suggest that gene conversion is responsible for the maintained similarity of the Hbbs genes. Furthermore, we attribute the divergence of the Hbbd genes in part to the absence of a region of simple-sequence DNA within the large intervening sequence of beta dmin. We propose that this region of DNA plays a role in facilitating gene conversion. The deletion of this area in beta dmin introduced a block of nonhomology between the beta dmaj-beta dmin gene pair and thus may have inhibited further gene correction within the Hbbd haplotype.
Platelet MAO activity in posttraumatic stress disorder
Authors: J Davidson, S Lipper, C D Kilts, S Mahorney, E Hammett
Journal: American Journal of Psychiatry (1985)

Platelet monoamine oxidase (MAO) activity was assessed in 23 patients with posttraumatic stress disorder and 19 age-matched male control subjects. An overall significantly lower MAO activity was observed in the posttraumatic stress disorder group. When the group was divided into those with and those without a history of alcohol abuse, only the former group differed significantly from control subjects. The heuristic importance of these findings is discussed.
Conditional deletion of <i>L1CAM</i> in human neurons impairs both axonal and dendritic arborization and action potential generation
Authors: Christopher Patzke, Claudio Acuna, Louise R. Giam, Marius Wernig, Thomas C. Südhof
Journal: The Journal of Experimental Medicine (2016)

Hundreds of L1CAM gene mutations have been shown to be associated with congenital hydrocephalus, severe intellectual disability, aphasia, and motor symptoms. How such mutations impair neuronal function, however, remains unclear. Here, we generated human embryonic stem (ES) cells carrying a conditional L1CAM loss-of-function mutation and produced precisely matching control and L1CAM-deficient neurons from these ES cells. In analyzing two independent conditionally mutant ES cell clones, we found that deletion of L1CAM dramatically impaired axonal elongation and, to a lesser extent, dendritic arborization. Unexpectedly, we also detected an ∼20–50% and ∼20–30% decrease, respectively, in the levels of ankyrinG and ankyrinB protein, and observed that the size and intensity of ankyrinG staining in the axon initial segment was significantly reduced. Overexpression of wild-type L1CAM, but not of the L1CAM point mutants R1166X and S1224L, rescued the decrease in ankyrin levels. Importantly, we found that the L1CAM mutation selectively decreased activity-dependent Na+-currents, altered neuronal excitability, and caused impairments in action potential (AP) generation. Thus, our results suggest that the clinical presentations of L1CAM mutations in human patients could be accounted for, at least in part, by cell-autonomous changes in the functional development of neurons, such that neurons are unable to develop normal axons and dendrites and to generate normal APs.
Abstract 17794: Modes of Failure and Cause of Death in Children with Functional Single Ventricle Physiology Following Contemporary Total Cavopulmonary Connection Completion
Authors: Yasuhiro Kotani, Devin Chetan, Jiaquan Zhu, Lisa Zhao, Luc Mertens, Andrew Redington, John Coles, Christopher Caldarone, Glen Van Arsdell, Osami Honjo
Journal: Circulation (2012)

Background: We hypothesized that modes of Fontan failure may predict the mode and timing of subsequent death following the contemporary form of Fontan completion. Methods: Patient records were revi...
Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine
Authors: Ioana Alesutan, Martina Feger, Rashad Tuffaha, Tatsiana Castor, Katharina Musculus, Salvatore S. Buehling, Christian L. Heine, Makoto Kuro-O, Burkert Pieske, Kurt Schmidt, Andreas Tomaschitz, Winfried Maerz, Stefan Pilz, Andreas Meinitzer, Jakob Voelkl, Florian Lang
Journal: Cardiovascular Research (2016)

Reduced homoarginine plasma levels are associated with unfavourable cardiovascular outcome in chronic kidney disease (CKD). Cardiovascular events in CKD are fostered by vascular calcification, an active process promoted by hyperphosphatemia and involving osteo-/chondrogenic transformation of vascular smooth muscle cells (VSMCs). The present study explored the effect of homoarginine on phosphate-induced osteo-/chondrogenic signalling and vascular calcification. Experiments were performed in hyperphosphatemic klotho-hypomorphic mice (kl/kl), in subtotal nephrectomy and vitamin D3–overload mouse calcification models and in primary human aortic smooth muscle cells (HAoSMCs). As a result, plasma homoarginine levels were lower in kl/kl mice than in wild-type mice and in both genotypes significantly increased by lifelong treatment with homoarginine. Surprisingly, homoarginine treatment of kl/kl mice and of mice with renal failure after subtotal nephrectomy augmented vascular calcification and enhanced the transcript levels of plasminogen activator inhibitor 1 (Pai1) and of osteogenic markers Msx2, Cbfa1, and Alpl. Similarly, homoarginine treatment of HAoSMCs increased phosphate-induced calcium deposition, ALP activity, as well as PAI1, MSX2, CBFA1, and ALPL mRNA levels. Homoarginine alone up-regulated osteo-/chondrogenic signalling and indicators of oxidative stress in HAoSMCs. Furthermore, homoarginine reduced citrulline formation from arginine by nitric oxide (NO) synthase (NOS) isoforms. NO formation by NOS was reduced when using homoarginine as a substrate instead of arginine. The osteoinductive effects of homoarginine were mimicked by NOS inhibitor L-NAME and abolished by additional treatment with the NO donors DETA-NONOate and PAPA-NONOate or the antioxidants TEMPOL and TIRON. Furthermore, homoarginine augmented vascular calcification and aortic osteo-/chondrogenic signalling in mice after vitamin D3-overload, effects reversed by the NO donor molsidomine. Homoarginine augments osteo-/chondrogenic transformation of VSMCs and vascular calcification, effects involving impaired NO formation from homoarginine.
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7
Authors: Sophie D. Fosså, Fredrik Wiklund, Olbjørn Klepp, Anders Angelsen, Arne Solberg, Jan-Erik Damber, Morten Hoyer, Anders Widmark
Journal: European Urology (2016)